Trial Profile
A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Valsartan (Primary) ; Atenolol; Hydrochlorothiazide
- Indications Hypertension
- Focus Pharmacodynamics
- Sponsors Novartis
- 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
- 27 Oct 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
- 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.